Published December 12, 2014 | Version v1
Journal article

Dosimetric analysis of the brachial plexus among patients with breast cancer treated with post-mastectomy radiotherapy to the ipsilateral supraclavicular area: report of 3 cases of radiation-induced brachial plexus neuropathy

  • 1. Department of Radiation Oncology, Xiamen Cancer Center, the First Affiliated Hospital of Xiamen University, Xiamen, 361003 People's Republic of (China)
  • 2. Department of Radiation Oncology, Collaborative Innovation Center of Cancer Medicine, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, 510060 People's Republic of (China)
  • 3. Department of Obstetrics and Gynecology, Xiamen Cancer Center, the First Affiliated Hospital of Xiamen University, Xiamen, 361003 People's Republic of (China)
  • 4. Department of Basic Medical Science, Medical College, Xiamen University, Xiamen, 361003 People's Republic of (China)

Description

The purpose of this study was to evaluate the brachial plexus (BP) dose of postmastectomy radiotherapy (PMRT) to the ipsilateral supraclavicular (ISCL) area, and report the characteristics of radiation-induced brachial plexus neuropathy (RIBPN). The BP dose of 31 patients who received adjuvant PMRT to the ISCL area and chest wall using three-dimensional conformal radiotherapy (3DCRT) and the records of 3 patients with RIBPN were retrospectively analyzed based on the standardized Radiation Therapy Oncology Group-endorsed guidelines. The total dose to the ISCL area and chest wall was 50 Gy in 25 fractions. Patients with a higher number of removed lymph nodes (RLNs) had a higher risk of RIBPN (hazard ratio [HR]: 1.189, 95% confidence interval [CI]: 1.005-1.406, p = 0.044). In 31 patients treated with 3DCRT, the mean dose to the BP without irradiation to the ISCL area was significantly less than that with irradiation to the ISCL area (0.97 ± 0.20 vs. 44.39 ± 4.13 Gy, t = 136.75, p <0.001). In the 3DCRT plans with irradiation to the ISCL area and chest wall, the maximum dose to the BP was negatively correlated with age (r = −0.40, p = 0.026), body mass index (BMI) (r = −0.44, p = 0.014), and body weight (r = −0.45, p = 0.011). Symptoms of the 3 patients with RIBPN occurred 37–65 months after radiotherapy, and included progressive upper extremity numbness, pain, and motor disturbance. After treatment, 1 patient was stable, and the other 2 patients' symptoms worsened. The incidence of RIBPN was higher in patients with a higher number of RLNs after PMRT. The dose to the BP is primarily from irradiation of the ISCL area, and is higher in slim and young patients. Prevention should be the main focus of managing RIBPN, and the BP should be considered an organ-at-risk when designing a radiotherapy plan for the ISCL area

Availability note (English)

Available from http://dx.doi.org/10.1186/s13014-014-0292-5; Available from http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4271326

Additional details

Publishing Information

Journal Title
Radiation Oncology (Online)
Journal Volume
9
Journal Page Range
vp.
ISSN
1748-717X

INIS

Country of Publication
United Kingdom
Country of Input or Organization
International Atomic Energy Agency (IAEA)
INIS RN
47066227
Subject category
S62: RADIOLOGY AND NUCLEAR MEDICINE;
Descriptors DEI
CHEST; DOSIMETRY; GY RANGE 01-10; GY RANGE 10-100; IRRADIATION; LYMPH NODES; MAMMARY GLANDS; NEOPLASMS; PATIENTS; RADIATION DOSES; RADIOTHERAPY
Descriptors DEC
ABSORBED DOSE RANGE; BODY; DISEASES; DOSES; GLANDS; GY RANGE; LYMPHATIC SYSTEM; MEDICINE; NUCLEAR MEDICINE; ORGANS; RADIATION DOSE RANGES; RADIOLOGY; THERAPY

Optional Information

Copyright
Copyright (c) Wu et al.
Notes
PMCID: PMC4271326; PMID: 25499205; PUBLISHER-ID: 292; OAI: oai:pubmedcentral.nih.gov:4271326; licensee BioMed Central Ltd. 2014